BioMarin Pharmaceutical EBITDA 2011-2026 | BMRN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA BioMarin Pharmaceutical

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
489 M	581 M	290 M	263 M	25.7 M	61.7 M	-51.3 M	-125 M	-93.2 M	-231 M	-299 M	-142 M	-137 M	-91.5 M	-32.5 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
581 M	-299 M	33.8 M

Quarterly EBITDA BioMarin Pharmaceutical

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
287 M	246 M	-	125 M	132 M	116 M	-	40.4 M	75 M	88.8 M	-	6.28 M	48.7 M	165 M	-	28.8 M	23.5 M	53.1 M	-	21.9 M	10.2 M	131 M	-	83.5 M	7.42 M	-31.5 M	-	55.2 M	19.3 M	-20.7 M	-	45.5 M	-315 K	-796 K	-	16.7 M	-525 M	-62.2 M	-	-47.6 M	-42 M	-55 M	-	51.1 M	6.8 M	-14.5 M	-	-13.2 M	4.16 M	-21.6 M	-	22.9 M	-9.18 M	-11.3 M	-	10.9 M	17.9 M	10.9 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
287 M	-525 M	24.9 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Xeris Pharmaceuticals XERS	26.2 M	$ 6.03	-1.55 %	$ 885 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
UroGen Pharma Ltd. URGN	-125 M	$ 19.2	-11.52 %	$ 554 M	Israel
uniQure N.V. QURE	-171 M	$ 10.89	-30.36 %	$ 530 M	Niderland
GT Biopharma GTBP	-12.4 M	$ 0.47	-2.41 %	$ 892 K	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
AbCellera Biologics ABCL	-199 M	$ 3.74	3.6 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	-146 M	$ 3.36	0.86 %	$ 1.2 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	-467 M	$ 29.16	-3.54 %	$ 1.69 B	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Завод ДИОД DIOD	85.9 M	-	-	-	Russia
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Alector ALEC	-150 M	$ 2.19	-9.77 %	$ 226 M	USA
Entera Bio Ltd. ENTX	-11.1 M	$ 1.38	-0.72 %	$ 63.3 M	Israel
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	-103 M	$ 4.21	-2.32 %	$ 299 M	USA
Teligent, Inc. TLGT	48.6 M	-	-13.85 %	$ 16.1 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	-31 M	$ 0.84	-4.24 %	$ 27.9 M	Israel
Viela Bio, Inc. VIE	-151 M	-	-	$ 2.91 B	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	-47.1 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
AbbVie ABBV	15.8 B	$ 233.57	0.64 %	$ 413 B	USA
Blueprint Medicines Corporation BPMC	16.3 M	-	-	$ 8.14 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
AIM ImmunoTech AIM	-19.9 M	$ 0.8	-11.6 %	$ 38.5 M	USA
Aptorum Group Limited APM	1.19 M	$ 0.83	5.37 %	$ 4.53 M	China
Apellis Pharmaceuticals APLS	57 M	$ 20.67	-1.38 %	$ 2.61 B	USA